Literature DB >> 8094471

Cytoskeletal agents inhibit motility and adherence of human tumor cells.

M L Stracke1, M Soroush, L A Liotta, E Schiffmann.   

Abstract

Cytoskeletal agents have been demonstrated to inhibit stimulated motility and substrate adherence by the human tumor cell line, A2058. cis-tubulozole, taxol, and cytochalasin D were tested for their effects on chemotaxis in response to a tumor cytokine, autocrine motility factor, and on adherence to several substrata: laminin- and gelatin-coated dishes as well as tissue culture plastic. Cytochalasin D, which inhibits microfilament polymerization, abolished stimulated motility. Taxol, which stabilizes microtubules, decreased stimulated motility to a greater degree than cis-tubulozole, which inhibits microtubular polymerization. In contrast, cis-tubulozole had the greatest inhibitory effect on adherence with a gelatin substratum more affected (100% inhibition) than tissue culture plastic (90%) or laminin substratum (52%). Taxol affected adherence in the same order but less than cis-tubulozole. Cytochalasin D had no significant effect on adherence to laminin with moderate inhibition of adherence to tissue culture plastic or gelatin. These data suggest that, in these tumor cells, microfilaments are more crucial for motility than adherence, but the dynamic polymerization and depolymerization of microtubules are required for both types of cellular activities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094471     DOI: 10.1038/ki.1993.25

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.

Authors:  B Liu; E Staren; T Iwamura; H Appert; J Howard
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  Convergent regulation of skeletal muscle Ca2+ channels by dystrophin, the actin cytoskeleton, and cAMP-dependent protein kinase.

Authors:  Barry D Johnson; Todd Scheuer; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

3.  Taxol encapsulation in poly(epsilon-caprolactone) microspheres.

Authors:  S K Dordunoo; J K Jackson; L A Arsenault; A M Oktaba; W L Hunter; H M Burt
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 4.  Colorectal cancer: from prevention to personalized medicine.

Authors:  Gemma Binefa; Francisco Rodríguez-Moranta; Alex Teule; Manuel Medina-Hayas
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 5.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

6.  Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro.

Authors:  A J Terzis; F Thorsen; O Heese; T Visted; R Bjerkvig; O Dahl; H Arnold; G Gundersen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Using cytochalasins to improve current chemotherapeutic approaches.

Authors:  Matthew Trendowski
Journal:  Anticancer Agents Med Chem       Date:  2015       Impact factor: 2.505

8.  The actin cytoskeleton as a sensor and mediator of apoptosis.

Authors:  Melissa Desouza; Peter W Gunning; Justine R Stehn
Journal:  Bioarchitecture       Date:  2012-05-01

9.  Fluid-flow induced wall shear stress and epithelial ovarian cancer peritoneal spreading.

Authors:  Liron Avraham-Chakim; David Elad; Uri Zaretsky; Yoel Kloog; Ariel Jaffa; Dan Grisaru
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.